XIAP and osteosarcoma: The nanoformulation exhibited good anticancer performance, and a synergistic antitumor effect against the human osteosarcoma cell lines, including Saos-2 and MG-63, likely due to down-regulation of X-linked inhibitor of apoptosis (XIAP), survivin, and human telomerase catalytic subunit (hTERT) (p < 0.0001), which reduced toxicity in normal cells [94].